Last reviewed · How we verify
Isoflurane + analgesic drug
Isoflurane provides general anesthesia by enhancing inhibitory GABAergic neurotransmission and suppressing excitatory glutamatergic signaling, while a co-administered analgesic drug provides pain relief through opioid or non-opioid pathways.
Isoflurane provides general anesthesia by enhancing inhibitory GABAergic neurotransmission and suppressing excitatory glutamatergic signaling, while a co-administered analgesic drug provides pain relief through opioid or non-opioid pathways. Used for General anesthesia with analgesia for surgical procedures.
At a glance
| Generic name | Isoflurane + analgesic drug |
|---|---|
| Sponsor | University Hospital, Brest |
| Drug class | General anesthetic + analgesic combination |
| Target | GABA-A receptor (isoflurane); NMDA receptor antagonism (isoflurane); analgesic target unspecified |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
Isoflurane is a volatile anesthetic that depresses central nervous system activity by potentiating GABA-A receptors and inhibiting NMDA glutamate receptors, producing unconsciousness and amnesia. The analgesic component (specific agent unspecified) works synergistically to provide perioperative pain control, potentially through opioid receptor agonism, COX inhibition, or other pain-modulating mechanisms. This combination approach aims to optimize anesthesia depth and analgesia during surgical procedures.
Approved indications
- General anesthesia with analgesia for surgical procedures
Common side effects
- Postoperative nausea and vomiting
- Respiratory depression
- Hypotension
- Bradycardia
- Emergence delirium
Key clinical trials
- Dexamethasone As Adjuvant for Pre - emptiveTransversusAbdominus Muscle Plane Block (NA)
- Comparison of an Inhaled Sedation Strategy to an Intravenous Sedation Strategy in Intensive Care Unit Patients Treated With Invasive Mechanical Ventilation (PHASE3)
- Deep Parasternal Intercostal Plane Block Versus Erector Spinae Plane Block in Pediatric Cardiac Patients Undergoing Primary Repair of Septal Defects Via Median Sternotomy (PHASE3)
- The Effect of Superficial Parasternal Intercostal Plane Block on Pulmonary Function Tests After Cardiac Surgery (NA)
- The Ratio of Hypnotic to Analgesic Potency of Volatile Anesthetics (PHASE3)
- Ketamine Versus Magnesium as Analgesic Adjuvants in Pediatric Adenotonsillectomy (PHASE4)
- Different Volumes of Local Anesthetics in Thoracolumbar Interfascial Plane Block (NA)
- Opioid-free Anesthesia for Open Cardiac Surgery: A Prospective Randomized Controlled Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isoflurane + analgesic drug CI brief — competitive landscape report
- Isoflurane + analgesic drug updates RSS · CI watch RSS
- University Hospital, Brest portfolio CI